GANX · Gain Therapeutics, Inc. · Executive Compensation
$1.64
+0.03 (+1.55%)
At close · Oct 9
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our projected cash outflows for the upcoming periods raise substantial doubt about our ability to continue as a going concern for at least 12 months from the issuance of the financial statements included elsewhere in this Quarterly Report. We will need to raise additional capital to fund continued operations beyond the second quarter of 2027.”View the 10-Q filed Aug 11, 2026
Market Cap
$71.58M
Shares
43.64M
Volume · Oct 9
328.69K
Avg daily vol (3M)
491.88K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Eric I. Richman | Former Chief Executive Officer | $1,271,732 |
| Matthias Alder | Chief Executive Officer and former Chief Operating Officer | $1,075,990 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Matthias Alder | Chief Executive Officer and former Chief Operating Officer | $954,034 |
| Eric I. Richman | Former Chief Executive Officer | $600,165 |
| Salvatore Calabrese | Former Chief Financial Officer | $345,389 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Gene Mack | interim Chief Financial Officer | Appointed | 2026-09-28 |
| Gianluca Fuggetta | Senior Vice President of Finance, principal financial officer, and principal accounting officer | Resigned | 2026-09-28 |
| Eric Richman | Board of Directors | Resigned | 2025-10-09 |
| Gene Mack, MBA | member of the Company's Board of Directors | Appointed | 2025-01-07 |
| Gene Mack, MBA | President and Chief Executive Officer | Appointed | 2025-01-07 |
| Gianluca Fuggetta | Senior Vice President, Finance and Principal Financial Officer | Appointed | 2025-01-07 |
| Gene Mack | Chief Financial Officer | Resigned | 2025-01-07 |
| Gene Mack | member of the Company’s board of directors | Appointed | 2025-01-07 |
| Gene Mack | President and Chief Executive Officer | Appointed | 2025-01-07 |
| Khalid Islam | Executive Chairman of the Board | Appointed | 2024-06-28 |
| Gene Mack | Interim Chief Executive Officer | Appointed | 2024-06-28 |
| Matthias Alder | Board | Resigned | 2024-06-28 |
| Matthias Alder | Chief Executive Officer | Resigned | 2024-06-28 |
| Gene Mack, MBA | Chief Financial Officer | Appointed | 2024-04-08 |
| Gene Mack | Principal Financial Officer | Appointed | 2024-04-08 |
| Gene Mack | Chief Financial Officer | Appointed | 2024-04-08 |
| C. Evan Ballantyne | Chief Financial Officer | Resigned | 2024-02-22 |
| Salvatore Calabrese | Chief Financial Officer | Terminated | 2023-04-28 |
| C. Evan Ballantyne | Chief Financial Officer | Appointed | 2023-04-12 |
| Salvatore Calabrese | Chief Financial Officer | Terminated | 2023-04-12 |
| C. Evan Ballantyne | Chief Financial Officer | Appointed | 2023-04-12 |
| Gianluca Fuggetta | Principal Accounting Officer | Appointed | 2022-12-16 |
| Matthias Alder | Director | Appointed | 2022-09-20 |
| Matthias Alder | President and Chief Executive Officer | Appointed | 2022-09-20 |
| Eric Richman | Chief Executive Officer | Resigned | 2022-09-20 |